drugset / Trial / NCT02107144

The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease

NCT02107144

Phase 4 Completed 71 enrolled Clinical Hospital Center Zemun
RandomizedParallel-groupSingle-blindTreatment

Summary

The study should enrol 50 patients with stable coronary artery disease scheduled for elective percutaneous coronary intervention of single, de novo lesion of native coronary artery. Patients will be randomized to orally given trimetazidine on top of standard medical therapy for stable coronary artery disease versus standard therapy only. The randomization will begin 48 hrs before intervention. Index of microcirculatory resistance (IMR) will be measured by thermodilution method using coronary pressure and temperature wire before and after stent implantation. Echocardiography will be performed before intervention and within 30 minutes after intervention. Patients will be followed clinically for a period of one year.

Timeline

Start
2014-04
Primary completion
2023-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Trimetazidine Small molecule 70 mg Oral